Femasys Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.4%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$3.5Mnext fiscal year
FY EPS (est.)
-$6.00next fiscal year
Monitoring Framework
Key Performance Indicators
Annual Sales Annually2.3M
Quarterly Sales Quarterly424.9K
Cash and Cash Equivalents Quarterly5.4M
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: $1.00 closing bid priceAction: Regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the July 13, 2026 deadline, potentially utilizing a reverse stock split if necessary.
- Cash Runway and Going Concern RiskTrigger: Third Quarter of 2026Action: Secure additional financing or capital injection to extend the cash runway beyond Q3 2026 to support ongoing clinical trials and commercial execution.
- FemBloc FINALE Pivotal Clinical Trial EnrollmentTrigger: Patient enrollment milestonesAction: Monitor patient enrollment progress in the FINALE pivotal clinical trial evaluating FemBloc to support the pathway toward potential U.S. FDA approval.
Research as of 19 Jun 2026